Cassava Sciences (SAVA) Resolves SEC Investigation

Go back to Cassava Sciences (SAVA) Resolves SEC Investigation

Cassava Sciences Resolves SEC Investigation

September 26, 2024 6:15 PM UTC

AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Cassava or the Company) (Nasdaq: SAVA), a biotechnology company focused on Alzheimers disease, today announced that it has reached a settlement with the U.S. Securities and Exchange Commission (SEC) of negligence-based disclosure charges that resolve a previously-disclosed SEC investigation into statements made by the Company pertaining to the results of its 2020 Phase 2b clinical trial of simufilam and related matters. Two former senior employees of the Company also settled negligence-based disclosure charges brought by the SEC.

Cassava,... More